Company profile
Regend Therapeutics
Privately held: no public share price · China
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Airway epithelial regeneration (autologous basal cells)Cell therapy | Chronic Obstructive Pulmonary Disease | |
| Phase 1 | Renal progenitor cell therapyCell therapy | Type 2 DiabetesChronic Kidney Disease | |
| Phase 1 | Airway epithelial regeneration (autologous basal cells)Cell therapy | Chronic Obstructive Pulmonary Disease |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.